In OSAS patients, a significant positive correlation was detected between oxygen levels (minimum and mean) at night and PAPP-A
Based on these findings, combining PAPP-A
and free [beta]-HCG may have utility.
Numerous studies have been performed using knock-out (KO) and transgenic (Tg) mouse models to understand the physiology of PAPP-A
, PAPP-A2, STC1, and STC2.
Comparison of various parameters between adverse and normal pregnancy outcomes Variable Adverse outcome Normal outcome p value (n=236) (n=632) Maternal age 30 (28-34) 29 (27-32) 0.001 (years) Maternal 61.5 (56-69.5) 60 (55-66.5) 0.007 weight (kg) CRL (mm) 59.6 (54.4-67.5) 60.0 (53.9-66.6) 0.602 Nasal bone 2.1 (1.8-2.3) 2.0 (1.8-2.3) 0.673 length (mm) Nuchal 1.34 (1.1-1.6) 1.31 (1.1-1.5) 0.37 translucency (mm) Free [beta]-hCG 1.22 (0.64-1.48) 1.17 (0.67-1.45) 0.465 (MoM) PAPP-A
(MoM) 1.15 (0.69-1.44) 1.22 (0.74-1.54) 0.178 CRL: crown-rump length; PAPP-A
: pregnancy associated plasma protein-A, Values are expressed as median, 25-75 percentiles
The posterior risk calculation of the 1st step of contingent screening was done from the measurements of CRL, PAPP-A
MoM and free [beta]-hCG MoM.
Table-III: Sensitivity specificity PPV and NPV of maternal serum PAPP-A
MoM at various cut-off levels in the prediction of pre-eclampsia.
A univariate analysis of PAPP-A
and free [beta]-hCG according to fetal weight at delivery shows lower median PAPP-A
in LBW group but no significant differences of free [beta]-hCG (Figure 3).
We analyzed DBSs for PAPP-A
and free hCG[beta] with the AutoDELFIA PAPP-A/Free hCG[beta] dual assay (kit reference B027-105) on the day after collection.
Pregnancy associated plasma protein-A (PAPP-A
) is an emerging biomarker amongst the biomarkers of plaque instability.
In general, the CVs for both analyte values (Figure 2, A) and MoM levels (Figure 2, B) are much tighter for hCG than for PAPP-A
and are relatively constant throughout the range of concentrations (about 12%).
Stepwise sequential screening divides patients into two risk groups that are based on nuchal translucency, PAPP-A
, and free [beta]-hCG measures in the first trimester, with those with a risk of greater than 1:30 receiving immediate CVS, and all others returning for second-trimester quad screening.
The approval covers assays for PAPP-A
and free hCGB run on PerkinElmer's DELFIA Xpress random access platform.